Literature DB >> 15947276

Clinical trials: is the Bayesian approach ready for prime time? Yes!

Donald A Berry1.   

Abstract

Mesh：

Year:  2005        PMID： 15947276     DOI： 10.1161/01.STR.0000170637.02692.14

Source DB:  PubMed          Journal:  Stroke        ISSN： 0039-2499            Impact factor:   7.914


× No keyword cloud information.
  5 in total

1.  Interpreting trial results in light of conflicting evidence: a Bayesian analysis of adjuvant chemotherapy for non-small-cell lung cancer.

Authors:  Rebecca A Miksad; Mithat Gönen; Thomas J Lynch; Thomas G Roberts
Journal:  J Clin Oncol       Date:  2009-03-23       Impact factor: 44.544

2.  A predictive probability design for phase II cancer clinical trials.

Authors:  J Jack Lee; Diane D Liu
Journal:  Clin Trials       Date:  2008       Impact factor: 2.486

Review 3.  Clinical trial design for endovascular ischemic stroke intervention.

Authors:  Osama O Zaidat; David S Liebeskind; Randall C Edgell; Catherine M Amlie-Lefond; Junaid S Kalia; Andrei V Alexandrov
Journal:  Neurology       Date:  2012-09-25       Impact factor: 9.910

4.  Bayesian methods to determine performance differences and to quantify variability among centers in multi-center trials: the IHAST trial.

Authors:  Emine O Bayman; Kathryn M Chaloner; Bradley J Hindman; Michael M Todd
Journal:  BMC Med Res Methodol       Date:  2013-01-16       Impact factor: 4.615

5.  Changing the Paradigm for the Treatment and Development of New Therapies for FSGS.

Authors:  Cathie Spino; Jordan S Jahnke; David T Selewski; Susan Massengill; Jonathan Troost; Debbie S Gipson
Journal:  Front Pediatr       Date:  2016-03-23       Impact factor: 3.418
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.